Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus NITRO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus NITRO DUR.
GONITRO vs NITRO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing cGMP, leading to vasodilation primarily in veins and arteries.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
None Documented
None Documented
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator